Tepkinly:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for Israeli Healthcare Professionals only.

       

      The first‑and‑only subcutaneous T‑Cell therapy

       

       

      The first‑and‑only subcutaneous T‑Cell therapy

      Experts sharing their experience and perspectives

      How Do We Turn Bispecific Antibody’s Evidence into Real Clinical Impact?
      Epcoritamab generates long-lasting complete responses, reflecting important survival gains in LBCL 3L+ including post CAR-T patients, "With median duration of complete response of almost 38 months, when the longest continuous CR with durable response is more than 4 years"

      How Do We Prevent and Manage Toxicities with Bispecific Antibodies?
      Reviewed key safety aspects across treatment journey - from pre-treatment assessment and individualized CRS prevention, to proactive infection prevention, maintenance IgG monitoring, and long-term surveillance of secondary malignancies.

      Third-Line FL: Individualizing Treatment Choices Between CAR-T and Bispecific?
      How Do We Turn Bispecific Antibody’s Evidence into Real Clinical Impact?Bispecific Abs for 3rd line FL
      Exploring the evolving clinical landscape of follicular lymphoma: efficacy, durability, and patient outcomes with bispecific antibodies.

      Which efficacy parameters
      are most crucial for you when evaluating treatment options for DLBCL patients at the 3L and beyond?

      What safety considerations
      are predominant when selecting a treatment regimen for DLBCL patients at the 3L and beyond?

      How significant is the mode of administration
      (subcutaneous vs intravenous) in your daily practice when treating DLBCL patients at 3L and beyond?

      When considering QoL
      what are the foremost concerns for your patients?

      Download the Dosing and Administration Guide for more information on how TEPKINLY is administered.

      DOWNLOAD HERE

      IL-EPCOR-240017. Date of preparation: July 2024.

       

       

      SCHEDULING TOOL

       

       

      Tepkinly PI – 4mg/0.8ml
      Tepkinly PI – 48 mg